Filtered By:
Specialty: Epidemiology
Vaccination: Varicella-Zoster Virus Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 95 results found since Jan 2013.
Sequential Data-Mining for Adverse Events after Recombinant Herpes Zoster Vaccination Using the Tree-Based Scan Statistic
In this study, the binomial tree-based scan statistic was applied sequentially to detect adverse events in Days 1-28 compared with Days 29-56 after recombinant herpes zoster (RZV) vaccination, with 5 looks at the data and formal adjustment for the repeated analyses over time. IBM Marketscan data on commercially insured persons 50+ years of age receiving RZV during January 1, 2018-May 5, 2020 were used. With 999,876 doses of RZV included, statistically significant signals were detected only for unspecified adverse effects/complications following immunization, with attributable risks as low as 2 excess cases per 100,000 vacc...
Source: Am J Epidemiol - October 13, 2022 Category: Epidemiology Authors: W Katherine Yih Martin Kulldorff Inna Dashevsky Judith C Maro Source Type: research
Active Post-Licensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
Am J Epidemiol. 2022 Oct 4:kwac170. doi: 10.1093/aje/kwac170. Online ahead of print.ABSTRACTRecombinant zoster vaccine (RZV) (Shingrix; GlaxoSmithKline, Brentford, United Kingdom) is an adjuvanted glycoprotein vaccine that was licensed in 2017 to prevent herpes zoster and its complications in older adults. In this prospective, post-licensure Vaccine Safety Datalink (VSD) study using electronic health records, we sequentially monitored a real-world population of adults aged 50 years and older who received care at multiple VSD health systems in the United States to identify potential increased risks of 10 pre-specified prior...
Source: Am J Epidemiol - October 4, 2022 Category: Epidemiology Authors: Jennifer C Nelson Ernesto Ulloa-P érez Onchee Yu Andrea J Cook Michael L Jackson Edward A Belongia Matthew F Daley Rafael Harpaz Elyse O Kharbanda Nicola P Klein Allison L Naleway Hung-Fu Tseng Eric S Weintraub Jonathan Duffy W Katherine Yih Lisa A Jacks Source Type: research
A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
Am J Epidemiol. 2022 Feb 12:kwac030. doi: 10.1093/aje/kwac030. Online ahead of print.ABSTRACTThe recombinant herpes zoster vaccine (RZV), approved as a 2-dose series in the U.S. in October 2017, has proven highly effective and generally safe. However, a small risk of Guillain-Barré syndrome (GBS) after vaccination was identified post-approval, and questions remain about other possible adverse events. This data-mining study assessed RZV safety in the U.S. using the self-controlled tree-temporal scan statistic, scanning data on thousands of diagnoses recorded during follow-up to detect any statistically unusual temporal clu...
Source: Am J Epidemiol - February 13, 2022 Category: Epidemiology Authors: W Katherine Yih Martin Kulldorff Inna Dashevsky Judith C Maro Source Type: research
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
This report updates previous ACIP recommendations for the prevention of herpes zoster (1,3).PMID:35051134 | DOI:10.15585/mmwr.mm7103a2
Source: MMWR Morb Mortal Wkl... - January 20, 2022 Category: Epidemiology Authors: Tara C Anderson Nina B Masters Angela Guo Leah Shepersky Andrew J Leidner Grace M Lee Camille N Kotton Kathleen L Dooling Source Type: research
Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
Ther Adv Vaccines Immunother. 2021 Nov 30;9:25151355211057479. doi: 10.1177/25151355211057479. eCollection 2021.ABSTRACTAn adjuvanted recombinant zoster vaccine (RZV) is licensed for the prevention of herpes zoster. This paper reviews its safety and reactogenicity. A pooled analysis of two pivotal randomized Phase-3 trials (NCT01165177, NCT01165229) in adults ⩾50 years found that more solicited adverse events (AEs) were reported with RZV than placebo. Injection site pain was the most common solicited AE (RZV: 78.0% participants; placebo: 10.9%). Grade-3 pain occurred in 6.4% of RZV and 0.3% of placebo recipients. Myalgia...
Source: Adv Data - January 10, 2022 Category: Epidemiology Authors: Joseph Fiore Maribel Miranda Co-van der Mee Andr és Maldonado Lisa Glasser Phil Watson Source Type: research
Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018
MMWR Surveill Summ. 2021 May 14;70(3):1-26. doi: 10.15585/mmwr.ss7003a1.ABSTRACTPROBLEM/CONDITION: Adults are at risk for illness, hospitalization, disability and, in some cases, death from vaccine-preventable diseases, particularly influenza and pneumococcal disease. CDC recommends vaccinations for adults on the basis of age, health conditions, prior vaccinations, and other considerations. Updated vaccination recommendations from CDC are published annually in the U.S. Adult Immunization Schedule. Despite longstanding recommendations for use of many vaccines, vaccination coverage among U.S. adults remains low.REPORTING PER...
Source: MMWR Surveill Summ - May 13, 2021 Category: Epidemiology Authors: Peng-Jun Lu Mei-Chuan Hung Anup Srivastav Lisa A Grohskopf Miwako Kobayashi Aaron M Harris Kathleen L Dooling Lauri E Markowitz Alfonso Rodriguez-Lainz Walter W Williams Source Type: research
